Monitor the special meeting outcome on October 12 for reverse split approval; if passed, watch for Board's decision on exact split ratio and timing before year-end, which could affect Nasdaq listing compliance and share price dynamics for this $54M market cap stock.
Price Chart
Executive Summary
Envoy Medical filed definitive additional proxy materials (DEFA14A) for a special meeting on October 12, 2026, seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-25, and an adjournment proposal. The filing is routine proxy solicitation by management with no financial data or material corporate event disclosed. The reverse split proposal is a typical Nasdaq compliance measure for a micro-cap stock trading near $54M market cap, with no guarantee of execution or specific ratio disclosed.
Key Financial Metrics
Key Facts
- Special meeting scheduled for October 12, 2026, at 9:00 AM Central Time
- Proposal 1: Approve reverse stock split at ratio of 1-for-5 to 1-for-25, at Board's discretion, before December 31, 2026
- Proposal 2: Approve adjournment if needed to solicit more votes
- Record date for voting is August 19, 2026
- Board recommends voting FOR all proposals
- Paper copy request deadline is September 28, 2026
- Voting deadline is 11:59 PM Eastern on October 11, 2026
Financial Impact
No financial figures disclosed in filing; reverse stock split ratio range of 1:5 to 1:25 authorized but not yet executed
Risk Factors
- Reverse split may not be executed even if approved
- Potential delisting risk if reverse split fails to maintain Nasdaq minimum bid price
- Shareholder dilution concerns if split ratio is at the high end (1:25)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-096772 |
| Document: 0001213900-26-096772-index-headers.html | 0001213900-26-096772 |
| Document: 0001213900-26-096772-index.html | 0001213900-26-096772 |
| Document: 0001213900-26-096772.txt | 0001213900-26-096772 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $5.11 | awaiting T+60 | — | $6.51 (−27.40%) |
Oct 7, 2026 20d ago | 8-K | $0.6534 | awaiting T+60 | — | $6.51 (+896.33%) |
Sep 2, 2026 7w ago | DEFA14A | $0.7301 | awaiting T+60 | — | $6.51 (+791.66%) |
Aug 10, 2026 11w ago | 8-K | $0.7700 | awaiting T+60 | — | $6.51 (+745.45%) |
Jun 30, 2026 17w ago | 8-K | $0.7901 $0.7161 | ▼ −9.37% | ▼ −12.24% | $6.51 (+723.95%) |
Jun 17, 2026 18w ago | EFFECT | $0.6544 $0.7402 | ▼ −13.11% | ▼ −9.96% | $6.51 (−894.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers